Iranchild1: Створена сторінка: HSP90 interacts with LRRK2, and inhibition of this association leads to proteasomal degradation of LRRK2, but not via the lysosomal pathway [85, 86]. Furthermor...

2017-01-06T01:45:27Z

Створена сторінка: HSP90 interacts with LRRK2, and inhibition of this association leads to proteasomal degradation of LRRK2, but not via the lysosomal pathway [85, 86]. Furthermor...

Нова сторінка

HSP90 interacts with LRRK2, and inhibition of this association leads to proteasomal degradation of LRRK2, but not via the lysosomal pathway [85, 86]. Furthermore, it is noteworthy that an HSP90 inhibitor can significantly reduce the protein expression of WT-LRRK2 as well as G2019S-LRRK2 in primary cortical neurons derived from [http://www.selleckchem.com/products/MS-275.html MS-275 price] G2019S-transgenic mice and transiently transfected HEK293 cells [86]. Therefore, HSP90 may play a key role in maintaining the stability of mutant and WT-LRRK2 protein in living cells. Interestingly, this report also indicated that treatment of cultured cells with an HSP90 inhibitor promoted the interaction of LRRK2 with HSC70 [86], which is an isoform of the HSP70 family constitutively expressed in mammalian cells. On the basis of these findings, we propose that HSC70 acts as a physiological inhibitor of LRRK2-mediated tau phosphorylation by interfering with the binding of LRRK2 to GSK-3��, which is required for activation of the latter. In addition, HSC70 shows over 90% sequence homology [https://en.wikipedia.org/wiki/Quinapyramine Quinapyramine] with HSP70 [82]. HSP70 has been reported to prevent the aggregation of LRRK2 in cultured cells [83], suggesting that HSP70 can interact with LRRK2, and thus may also interfere with formation of the LRRK2/GSK-3�� complex. Previous pharmacological studies have shown that inhibition of GSK-3�� reduces tau phosphorylation and aggregation in a mouse model [87]. Some pharmaceutical companies are now conducting clinical or preclinical trials of GSK-3�� inhibitors with the aim of developing therapies for AD [88]. Up to now, a variety of effective small inhibitors for GSK-3�� have been developed using pharmacological approaches, but details of their possible side effects have yet to emerge. GSK-3�� was first discovered as a protein kinase involved in the physiological regulation of glycogen metabolism, and a number of subsequent biochemical studies demonstrated that it has diverse physiological functions in the cell [89]. Therefore, GSK-3�� inhibitors may affect not only the abnormal signaling pathway implicated in neurodegeneration but also normal pathways required for maintaining physiological function. Indeed, it has been shown that lithium, a classical GSK-3�� inhibitor, exerts toxic side effects in some elderly patients [88], and therefore such studies have now been discontinued. Based on our previous findings, it is expected that molecules interacting with ��-Syn or LRRK2, which [http://www.selleckchem.com/products/GDC-0449.html Stem Cells inhibitor] are capable of preventing the formation of ��-Syn- or LRRK2-mediated tripartite complexes with tau and GSK-3��, may act as more specific inhibitors of abnormal tau phosphorylation, without affecting normal tau phosphorylation by GSK-3��. As described above, HSP interacts with ��-Syn and LRRK2 [85, 90] and prevents their aggregation or accelerates their degradation. Therefore, HSP-inducing drugs may be useful therapeutic agents for PD based on inhibition of ��-Syn- and LRRK2-associated tau phosphorylation catalyzed by GSK-3��.

Indicators Concerning MS-275 You Should Know - Історія редагувань

Iranchild1: Створена сторінка: HSP90 interacts with LRRK2, and inhibition of this association leads to proteasomal degradation of LRRK2, but not via the lysosomal pathway [85, 86]. Furthermor...